With the recent ODAC review of the commerically available CAR-T therapies in relapsed/refractory myeloma post 1-3 lines of therapy, what is your preferred regimen/therapy for first relapse, and which are the situations where you would absolutely consider CAR-T therapy at first relpase?  


Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Winship Cancer Institute of Emory University
Well said
Sign in or Register to read more